The Wilms' Tumor Suppressor WT1 is Associated with Melanoma Proliferation

Overview

Journal Pflugers Arch

Specialty Physiology

Date 2007 Oct 4

PMID 17912546

Citations 27

Authors

Nicole Wagner

John Panelos

Daniela Massi

Kay-Dietrich Wagner

Affiliations

Soon will be listed here.

Abstract

Expression of the Wilms' tumor suppressor WT1 has been demonstrated in a variety of tumors and tumor cell lines, e.g., in breast cancer and melanoma cell lines. Its role is controversial, with evidence for both tumor-promoting and tumor-suppressing activities. In this paper, we show that WT1 is expressed in malignant melanoma in >80% of the tumor cells, but not in normal skin or benign melanocytic nevi in vivo. We detected an unusual shift of WT1 isoforms towards WT1(+17AA/+KTS) in melanoma. WT1 shared an overlapping expression with proliferating nuclear cell antigen and with Nestin and Zyxin, which are involved in melanoma cell proliferation. To investigate whether WT1 is directly involved in melanoma cell proliferation, we made use of an RNAi approach in vitro. WT1 silencing significantly reduced the expression of Nestin and Zyxin and resulted in inhibition of melanoma cell proliferation as determined by a reduced BrdU incorporation. These findings suggest a direct role of WT1 in melanoma proliferation, which might be mediated via Nestin and Zyxin. Furthermore, expression of WT1 in vivo clearly discriminates between benign acquired nevi and malignant melanomas and appears to be correlated with melanocytic atypia and malignancy.

Citing Articles

The Wilms' Tumor Suppressor WT1 in Cardiomyocytes: Implications for Cardiac Homeostasis and Repair.

Diaz Del Moral S, Wagner N, Wagner K Cells. 2025; 13(24.

PMID: 39768169 PMC: 11674098. DOI: 10.3390/cells13242078.

Prognostic signature and immunotherapeutic relevance of Focal adhesion signaling pathway-related genes in osteosarcoma.

Wu Z, Wang Z, Hua Z, Ji Y, Ye Q, Zhang H Heliyon. 2024; 10(21):e38523.

PMID: 39524888 PMC: 11550747. DOI: 10.1016/j.heliyon.2024.e38523.

Decreased expression of p53 is associated with down expression of zyxin in breast cancer.

Rostampour R, Bahremand K, Mohammadi H, Roghani S, Shakiba E, Goodarzi M Health Sci Rep. 2024; 7(8):e2288.

PMID: 39100715 PMC: 11294437. DOI: 10.1002/hsr2.2288.

The role of zyxin in signal transduction and its relationship with diseases.

Wu Z, Wu D, Zhong Q, Zou X, Liu Z, Long H Front Mol Biosci. 2024; 11:1371549.

PMID: 38712343 PMC: 11070705. DOI: 10.3389/fmolb.2024.1371549.

Links between melanoma germline risk loci, driver genes and comorbidities: insight from a tissue-specific multi-omic analysis.

Pudjihartono M, Golovina E, Fadason T, OSullivan J, Schierding W Mol Oncol. 2024; 18(4):1031-1048.

PMID: 38308491 PMC: 10994230. DOI: 10.1002/1878-0261.13599.

References

Wagner N, Wagner K, Schley G, Coupland S, Heimann H, Grantyn R . The Wilms' tumor suppressor Wt1 is associated with the differentiation of retinoblastoma cells. Cell Growth Differ. 2002; 13(7):297-305. View

Tuna M, Chavez-Reyes A, Tari A . HER2/neu increases the expression of Wilms' Tumor 1 (WT1) protein to stimulate S-phase proliferation and inhibit apoptosis in breast cancer cells. Oncogene. 2005; 24(9):1648-52. DOI: 10.1038/sj.onc.1208345. View

Wagner N, Wagner K, Hammes A, Kirschner K, Vidal V, Schedl A . A splice variant of the Wilms' tumour suppressor Wt1 is required for normal development of the olfactory system. Development. 2005; 132(6):1327-36. DOI: 10.1242/dev.01682. View

Hammes A, Guo J, LUTSCH G, Leheste J, Landrock D, Ziegler U . Two splice variants of the Wilms' tumor 1 gene have distinct functions during sex determination and nephron formation. Cell. 2001; 106(3):319-29. DOI: 10.1016/s0092-8674(01)00453-6. View

Norton A, Jordan S, Yeomans P . Brief, high-temperature heat denaturation (pressure cooking): a simple and effective method of antigen retrieval for routinely processed tissues. J Pathol. 1994; 173(4):371-9. DOI: 10.1002/path.1711730413. View

Amin K, Litzky L, Smythe W, Mooney A, Morris J, Mews D . Wilms' tumor 1 susceptibility (WT1) gene products are selectively expressed in malignant mesothelioma. Am J Pathol. 1995; 146(2):344-56. PMC: 1869867. View

Berwick M, Wiggins C . The current epidemiology of cutaneous malignant melanoma. Front Biosci. 2005; 11:1244-54. DOI: 10.2741/1877. View

Wagner N, Wagner K, Scholz H, Kirschner K, Schedl A . Intermediate filament protein nestin is expressed in developing kidney and heart and might be regulated by the Wilms' tumor suppressor Wt1. Am J Physiol Regul Integr Comp Physiol. 2006; 291(3):R779-87. DOI: 10.1152/ajpregu.00219.2006. View

van der Gaag E, Leccia M, Dekker S, Jalbert N, Amodeo D, Byers H . Role of zyxin in differential cell spreading and proliferation of melanoma cells and melanocytes. J Invest Dermatol. 2002; 118(2):246-54. DOI: 10.1046/j.0022-202x.2001.01657.x. View

10.

Balch C, Buzaid A, Soong S, Atkins M, Cascinelli N, Coit D . Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001; 19(16):3635-48. DOI: 10.1200/JCO.2001.19.16.3635. View

11.

Al-Hussaini M, Stockman A, Foster H, McCluggage W . WT-1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid ovarian carcinoma. Histopathology. 2004; 44(2):109-15. DOI: 10.1111/j.1365-2559.2004.01787.x. View

12.

Garbe C, Eigentler T . Diagnosis and treatment of cutaneous melanoma: state of the art 2006. Melanoma Res. 2007; 17(2):117-27. DOI: 10.1097/CMR.0b013e328042bb36. View

13.

Meier F, Satyamoorthy K, Nesbit M, Hsu M, Schittek B, Garbe C . Molecular events in melanoma development and progression. Front Biosci. 1998; 3:D1005-10. DOI: 10.2741/a341. View

14.

Hohenstein P, Hastie N . The many facets of the Wilms' tumour gene, WT1. Hum Mol Genet. 2006; 15 Spec No 2:R196-201. DOI: 10.1093/hmg/ddl196. View

15.

Burwell E, McCarty G, Simpson L, Thompson K, Loeb D . Isoforms of Wilms' tumor suppressor gene (WT1) have distinct effects on mammary epithelial cells. Oncogene. 2006; 26(23):3423-30. DOI: 10.1038/sj.onc.1210127. View

16.

Nakatsuka S, Oji Y, Horiuchi T, Kanda T, Kitagawa M, Takeuchi T . Immunohistochemical detection of WT1 protein in a variety of cancer cells. Mod Pathol. 2006; 19(6):804-14. DOI: 10.1038/modpathol.3800588. View

17.

Fuchs E, Merrill B, Jamora C, Dasgupta R . At the roots of a never-ending cycle. Dev Cell. 2001; 1(1):13-25. DOI: 10.1016/s1534-5807(01)00022-3. View

18.

Klein W, Wu B, Zhao S, Wu H, Klein-Szanto A, Tahan S . Increased expression of stem cell markers in malignant melanoma. Mod Pathol. 2006; 20(1):102-7. DOI: 10.1038/modpathol.3800720. View

19.

Wagner N, Wagner K, Theres H, Englert C, Schedl A, Scholz H . Coronary vessel development requires activation of the TrkB neurotrophin receptor by the Wilms' tumor transcription factor Wt1. Genes Dev. 2005; 19(21):2631-42. PMC: 1276736. DOI: 10.1101/gad.346405. View

20.

Burnet N, Jefferies S, Benson R, Hunt D, Treasure F . Years of life lost (YLL) from cancer is an important measure of population burden--and should be considered when allocating research funds. Br J Cancer. 2005; 92(2):241-5. PMC: 2361853. DOI: 10.1038/sj.bjc.6602321. View